Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
LLY compared with JBIO: revenue, margins and what each company keeps, and the suppliers and customers both name
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
JBIO
Jade Biosciences, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
LLY
ELI Lilly & Co
vs
JBIO
Jade Biosciences, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
LLY
ELI Lilly & Co
Change
1,416.65
▲
+0.52%
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
JBIO
Jade Biosciences, Inc.
Change
14.71
▲
+0.98%
Regular session
Nov 4 '26
Mkt cap
$926.6M
Revenue
—
Revenue
—
vs
Compare
Regular session
Nov 4 '26
LLY
ELI Lilly & Co
vs
JBIO
Jade Biosciences, Inc.
1,416.65
▲
+0.52%
Price
14.71
▲
+0.98%
$1.3T
Mkt cap
$926.6M
Q3 FY26
$24.4B
Revenue
—
FY25
$65.2B
Revenue
—
Change
Change
LLY
1,416.65
▲
+0.52%
vs
JBIO
14.71
▲
+0.98%
Regular session
Nov 4 '26
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
JBIO: latest quarter not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
LLY, solid
JBIO, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
25 more · LLY chain
›
Shared
0
No shared counterparties.
Only JBIO
3
—
Patheon Biologics
unlisted
supplier
—
WuXi Biologics (Hong Kong)
unlisted
supplier
—
WuXi Biologics Ireland
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR